

GP Perspective about being LGBTI Inclusive and Managing STIs in General Practice

Dr Garsing Wong, Auckland Central Medical and Health Clinic, 326/28
College Hill, Freemans Bay, Auckland 1011

akcentralmedical@gmail.com

Phone +64 9 3600250

Disclosures

- Cosmetic Medicine Clinic - Sapphire Appearance Medicine Clinic
- Honorary Clinical Lecturer - Department of General Practice and Primary Health Care, Faculty of Medical and Health Sciences, University of Auckland
- Former Chairman of The Royal New Zealand College of Urgent Care
- Former Secretary, Treasurer and Censor of The New Zealand Society of Cosmetic Medicine
- Give Suturing courses for RNZCUC and ACMA, Examiner for RNZCUC, Review Standards for NZSCM

I'm an ordinary man (Rex Harrison, My Fair lady)

- Ponsonby Auckland
- Lipodystrophy secondary to HIV medication
- Older kinds of drugs to treat HIV called protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) -- stavudine, or d4T (Zerit), and zidovudine, or AZT (Retrovir)
- Risk of HIV transmission was much lower than that for HBV
- Stable on environmental surface 72hrs vs 7 days
- Transmission 100x greater than HIV

Me too

- I educate my staff
- “Misunderstanding arising from ignorance breeds fear” Lester B Pearson, Nobel Peace Laureate, former PM Canada
- The patient from Christchurch
- Greeting

Managing STI's in General Practice

- Include routine screening for all sexually active and new patients as part of a general health check
- Be familiar with how to correctly take swabs
- Teach patients so that they can do this themselves
- Be familiar with the treatment protocols
- Keep stock of Ceftriaxone, Azithromycin, Benzathine Penicillin 1.8g must be long acting
- Get to know your friendly neighbourhood sexual health clinic

STI from GP Perspective focusing on MSM

- If you don't take a temperature, you won't find a fever
- How often
- PrEP every three months, by definition at greater risk
- All MSM at least annually (<https://nzshs.org/guidelines>)

MSM who fall into one or more categories below require testing up to 4 times a year:

- Any unprotected anal sex
- More than 10 sexual contacts in 6 months
- Participate in group sex
- Are HIV positive
- Use of PrEP or PEP
- Use recreational drugs during sex.

- Dr Karen Chung

AUCKLAND REGIONAL / Te rohe o Tāmaki Makaurau

HealthPathways

DRAFT

Home
Contact Us
Subscribe to Updates
Disclaimer

Search

- Infectious Mononucleosis
- Influenza
- Measles
- Meningococcal Disease
- Mumps
- Pertussis (Whooping Cough)
- **Post-exposure Prophylaxis for HIV (PEP)**
- Pre-exposure Prophylaxis for HIV (PrEP)
- Recurrent Staphylococcal Infection
- Rheumatic Fever
- Scabies
- Zika Virus
- Infectious Diseases Requests
- + Nephrology
- + Neurology
- + Oncology
- + Pain Management
- + Palliative Care
- + Respiratory
- + Rheumatology
- + Sexual Health
- + Sleep
- + Spinal Cord Impairment (SCI)
- + Mental Health and Addiction
- + Older Adults' Health
- + Pharmacology
- + Public Health
- + Specific Populations
- + Surgical
- + Women's Health
- + Our Health System
- Pathway Development Hub

Back < >

Post-exposure Prophylaxis for HIV (PEP)

Caution: This page is in development.

DRAFT PHASE
First edits

region's changes
Streamliners' changes
queries

This pathway is for patients exposed to HIV in non-occupational setting. See also [Blood or Body Fluid Exposures \(Needlestick Injury\)](#).

i [About post-exposure prophylaxis for HIV \(PEP\)](#)

About post-exposure prophylaxis for HIV (PEP)

Post-exposure prophylaxis (PEP) is the use of antiretroviral medications (ARVs) by HIV uninfected individuals to reduce the risk of acquiring HIV.

There is no data from randomised control trials of the use of PEP. Evidence for use has been extrapolated from animal data, mother to child transmission, and occupational exposure.

Assessment

1. History – ask about:
 - [exposure](#).

Exposure

- Date and time
- Type, including blood or body fluid involved, trauma, and first aid measures

Print Send Feedback

Auckland

- STI screening free at Auckland Sexual Health Clinics
- Syphilis and HIV free testing at NZAF and Body Positive

Search

Back < >

Print Send Feedback

- + Pain Management
- + Palliative Care
- + Respiratory
- + Rheumatology
- Sexual Health
 - Chlamydia
 - Contact Tracing (Partner Notification)
 - Epididymo-orchitis
 - Gender Diversity and Transgender Health
 - Gonorrhoea
 - Human Immunodeficiency Virus (HIV)
 - Human Papilloma Virus (HPV)
 - Pelvic Inflammatory Disease (PID)
 - Sexual Health Check
 - Female Sexual Health Check
 - **Male Sexual Health Check**
 - Syphilis
 - Urethritis
 - Vaginal Discharge
 - Vulvodynia
 - + Sexual Health Requests
- + Sleep
- + Spinal Cord Impairment (SCI)
- + Mental Health and Addiction
- + Older Adults' Health
- + Pharmacology
- + Public Health
- + Specific Populations
- + Surgical
- + Women's Health
- + Our Health System
- Pathway Development Hub

Male Sexual Health Check

Clinical Editor's Note

There is currently a syphilis epidemic with a large increase in confirmed cases in Auckland.

Assessment

1. If patients are:
 - aged < 25 years and sexually active, offer opportunistic testing when accessing healthcare, irrespective of risk factors. A HEEADSSS assessment is recommended as part of routine care for young people.
 - aged ≥ 25 years, offer testing according to [assessment of risk](#), presence of anogenital symptoms, or if patient requests a sexual health check.
2. If sexual contact of [chlamydia](#), [trichomoniasis](#), [urethritis](#), [epididymo-orchitis](#), or [pelvic inflammatory disease \(PID\)](#), complete testing:
 - [Treat contacts](#) empirically at the initial visit.
 - If patient is asymptomatic and concerned about a specific recent sexual event, test at the [recommended testing interval](#).
3. Check for history of urethral discharge, dysuria, urethral irritation, testicular pain, or swelling.
4. Ask about:
 - genital skin symptoms e.g., lumps, sores, rashes.
 - anorectal symptoms e.g., discharge or bleeding in men who have sex with men.
5. Examination:
 - Genital and perianal skin, inguinal lymph nodes, penis, scrotum, and testes.
 - Check for urethral discharge. May be clear, milky, or mucopurulent.
 - Signs of [epididymo-orchitis](#).

Assessment of risk

Risk is increased if within the last year, the patient has had:

- ≥ 2 sexual partners
- a new sexual partner in the last 3 months
- an STI
- a sexual partner with an STI.

- **-** Treat contacts empirically at the initial visit.

Treat contacts

- Patients with **chlamydia, gonorrhoea, trichomoniasis, urethritis, epididymo-orchitis, and pelvic inflammatory disease (PID)** need to have a sexual health check and be empirically treated at the initial visit. See relevant STI guideline for management of contacts.
- If contacts of **syphilis or HIV**, seek **sexual health advice**.

NAAT swab

- Nucleic Acid Amplification Test is NOT a culture

Anorectal swab

Drop-box shared with other pathway(s) – ask your writer for details

- Use a NAAT swab, which can be either clinician-collected or self-collected.
- Use the blue shaft swab. Discard the white shaft swab.
- Wet the swab with clean water or saline and gently insert 4 cm into anal canal, rotating and then replacing into the swab container.



NAAT Swab






Management



Practice Point!

Dual therapy is recommended routinely due to increasing anti-microbial resistance to gonorrhoea.

1. If gonorrhoea is suspected, or if patient is a contact of gonorrhoea, test and treat immediately. Do not wait for test results.
2. Uncomplicated gonorrhoea infections:
 -  Ceftriaxone 500 mg (available MPSO-endorsed "gonorrhoea")  [intramuscularly](#) and  azithromycin 1 g orally immediately.
 - If pregnant and breastfeeding, give ceftriaxone 500mg intramuscular immediately and azithromycin 1g orally immediately.
 - Both drugs pregnancy category B1.
 - Discuss infants born to mothers with untreated gonorrhoea infection with a [paediatrician](#).
 - Severe penicillin allergy – ceftriaxone is only contraindicated as a treatment option in patients who have genuine, immediate, or severe hypersensitivity to penicillin or other beta-lactam drugs. For management, seek urgent [specialist sexual health advice](#).

Syphilis – “the great imitator”

- Serological testing
- Auckland Labtest EIA if positive TPPA and RPR

The approach generally used by laboratories in New Zealand is to perform an initial test with EIA. If this is positive, the diagnosis is confirmed using TPPA. Disease activity is then determined using RPR.^{14,15} Depending on the patient-management system in use and the methodology of the local laboratory, clinicians either select “syphilis serology” on the laboratory request form or request the individual tests. BPAC

Determining the risk of exposure to syphilis

People with an increased risk of syphilis include those who:

- Originate from a country where syphilis is common, e.g. Sub-Saharan Africa, Asia-Pacific (especially Fiji), South America or Eastern Europe
- Have had sex with a person from a country where syphilis is prevalent
- Are male and have had sex with other males
- Are HIV positive or have had sex with someone who is HIV positive
- Have multiple sexual partners
- Have had sexual contact with a person diagnosed with syphilis



Figure 1: Penile chancre in primary syphilis (Supplied by Dermnet NZ)



Figure 2: Disseminated rash in secondary syphilis Pox (Supplied by Dermnet NZ /Dr John Adams)



Figure 3: Characteristic rash on the foot in secondary syphilis. (Supplied by Dr Edward Coughlan)



Figure 4: Condylomata lata in secondary syphilis (Supplied by Dermnet NZ/Dr John Adams)

There are two types of syphilis serology test - non-specific (non-treponemal) serology and specific (treponemal) serology. Non-specific tests detect antibodies that bind to antigens that are, or are similar to, those expressed by *Treponema pallidum* or expressed on host tissues during infection. These tests, such as the Rapid Plasma Reagin (RPR) and Venereal Disease Research Laboratory (VDRL) test, were traditionally used as screening tests for syphilis, and to measure disease activity and response to treatment. They are inexpensive to perform (compared to specific tests) but have a high false-positive rate, particularly in women who are pregnant, in people with cancers, autoimmune disorders, co-morbid viral infections, in older people and in people who use illicit drugs. BPAC

Specific tests detect antibodies that bind to proteins derived from *Treponema pallidum*. These tests, such as the *Treponema pallidum* Particle Agglutination (TPPA), *Treponema pallidum* Haemagglutination (TPHA) and Fluorescent *Treponema pallidum* Antibody (FTA) test, have commonly been used to confirm the diagnosis of syphilis. They are more expensive than non-specific tests, but have a low false-positive rate. More recently, the Enzyme immunoassay (EIA) and derivative immunoassays, such as the Chemiluminescent Microparticle Immunoassay (CMIA), that use specific *Treponema pallidum* antigens, have been developed. These tests are less expensive and have altered the way serology is used for testing for syphilis.

Interpreting syphilis serology

Syphilis serology results should be interpreted within the overall clinical picture, i.e. clinical examination, patient history and risk profile. Table 1 may be useful in aiding interpretation.

Table 1: Interpreting syphilis serology

EIA	TPPA	RPR	Interpretation
Non-Reactive	Not tested	Not tested	No evidence of syphilis, or too early, retest in one month if strong suspicion based on clinical evidence
Reactive	Non-Reactive	Non-Reactive	Possible early primary, latent or false-positive, retest in one month
Reactive	Non-Reactive	Reactive	Probable early primary, false positive possible but unlikely, retest in two weeks
Reactive	Reactive	Non-Reactive	Evidence of past infection or possible latent infection, history will help to differentiate
Reactive	Reactive	Reactive	Current syphilis

If positive, in NZ we refer

- If delay anticipated then Benzathine Benzylpenicillin IM or Doxycycline PO

Human Papilloma Virus

- Most common sexually transmitted disease
(<http://www.medsafe.govt.nz/Consumers/educational-material/gardasil9QandA.asp>)

How many people get cancers that can be caused by HPV infection in New Zealand?

The table shows how many people get different cancers that can be caused by HPV. The numbers show how many new cases in New Zealand there are in a year.



Table 1: Number of cancers that can be caused by HPV infection (numbers from 2014)

Cancer	Number of new cases per 100,000 of the population per year	Total number of registrations 2014	Estimated number of each cancer type caused by HPV infection*
Cervical	5.5 (Death in 1.4)	143	128 (9 out of 10)
Vulvar	2.0	70	48 (6.9 out of 10)
Vaginal	0.5	20	15 (7.5 out of 10)
Anal	1.0 in men, 1.5 in women	32 in men, 54 in women	28 in men, 50 in women (8.9 and 9.3 out of 10)
Penile	0.5	16	10 (6.3 out of 10)
Oropharyngeal	0.6 in men, 0.1 in women	16 in men, 4 in women	11 in men, 2 in women (7.2 and 6.3 out of 10)
Tonsil	1.9 in men, 0.4 in women	57 in men, 13 in women	47 in men, 11 in women (8.2 out of 10)

*Data on the numbers for each cancer estimated to be caused by HPV infection is from the US.

Anal Warts – Check under the bonnet

- Inspection
- DRE
- Any mass, anoscopy

- If evidence or suspected warts, refer for full examination.

How to describe

Clinical Presentation and Examination

Standardized anatomic description is important to adequately communicate findings on physical examination. Four distinct regions has been proposed for description⁸:

- Skin: 5 cm away from the anal opening upon simple examination
- Perianal (anal margin): within 5 cm of the anal opening
- Anal canal (Intra-anal): not visible, needs anoscopy to see
- Transformation zone: above the dentate line/squamous columnar junction

Symptoms

8. The etiology and epidemiology of anal cancer. *Welton ML, Sharkey FE, Kahlenberg MS Surg Oncol Clin N Am. 2004 Apr; 13(2):263-75.*

Review The etiology and epidemiology of anal cancer.
[Surg Oncol Clin N Am. 2004]

The types

- The HPV subtypes 6 and 11 are the cause of over 90% of the exophytic anal warts. They tend to be associated with low-grade dysplastic cellular changes (AIN 1).[21](#)
- HPV types 16 and 18 are responsible for most of the chronic infections that cause severe dysplasia (AIN 2 or AIN 3) and the development of cancer.[8,23](#)

What HPV vaccines are available?

There are three HPV vaccines approved for use in New Zealand.



Table 2: HPV vaccines

Vaccine name	Strains protected against	Cervical cancer - these strains cause up to	Penile cancer - these strains cause up to	Genital warts - these strains cause up to
Cervarix	16 and 18	7 out of 10 cases	5 out of 10 cases	0
Gardasil	6, 11, 16 and 18	7 out of 10 cases	5 out of 10 cases	9 out of 10 cases
Gardasil 9	6, 11, 16, 18, 31, 33, 45, 52 and 58	9 out of 10 cases	6 out of 10 cases	9 out of 10 cases

From 2017 Gardasil 9 will be the only vaccine given in schools, and will replace Gardasil in general practices once stocks run out.

Thank you

- Dr Garsing Wong
- akcentramedical@gmail.com
- +64 9 3600250